Article Per Year (5 Year)
p-Index From 2021 - 2026
2.681
P-Index
This Author published in this journals
All Journal Jurnal Kesehatan Andalas Jurnal Farmasi Klinik Indonesia Logista: Jurnal Ilmiah Pengabdian Kepada Masyarakat Eksakta : Berkala Ilmiah Bidang MIPA Jurnal Respirologi Indonesia Human Care Journal Unri Conference Series: Community Engagement Respiratory Science Bioscientia Medicina : Journal of Biomedicine and Translational Research Jurnal Ilmu Kesehatan Indonesia (JIKSI)
Ermayanti, Sabrina
Bagian Pulmonologi Dan Kedokteran Respirasi Fakultas Kedokteran Universitas Andalas, RSUP Dr. M. Djamil, Padang 25163, Indonesia
Agriculture, Biological Sciences & Forestry Humanities Astronomy Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Civil Engineering, Building, Construction & Architecture Computer Science & IT Energy Engineering Environmental Science Health Professions Immunology & microbiology Materials Science & Nanotechnology Mathematics Mechanical Engineering Medicine & Pharmacology Neuroscience Nursing Public Health

Published : 20 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 20 Documents
Search

 1   2 
Gambaran Riwayat Asma pada Pasien Rinitis Alergi di RSUP Dr. M. Djamil Padang Dolly Irfandy; Dolly Irfandy; Muhammad Farhan Ramadhan; Sabrina Ermayanti
Jurnal Ilmu Kesehatan Indonesia Vol 3 No 1 (2022): Maret 2022
Publisher : Fakultas Kedokteran, Universitas Andalas

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25077/jikesi.v3i1.874

Abstract

Latar Belakang: Rinitis alergi adalah penyakit inflamasi pada hidung yang sering ditemukan pada masyarakat. Asma merupakan salah satu komorbid yang dapat ditemukan pada penderita rinitis alergi. Hubungan rinitis alergi dan asma dijelaskan melalui konsep united airway disease. Objektif: Penelitian ini bertujuan untuk mengetahui gambaran dan karakteristik riwayat asma pada pasien rinitis alergi. Metode: Penelitian ini merupakan penelitian deskriptif retrospektif dengan desain cross-sectional. Penelitian ini dilakukan di RSUP Dr. M. Djamil Padang dengan jumlah sampel 78 pasien rinitis alergi. Hasil: Hasil penelitian didapatkan sebanyak 13 orang (16,7%) sampel memiliki riwayat asma. Karakteristik sampel dengan riwayat asma banyak ditemukan pada kelompok usia lebih dari 16 sampai 25 tahun (38,5%) dengan jenis kelamin terbanyak ditemukan pada perempuan (53,8%). Klasifikasi rinitis alergi persisten sedang-berat paling banyak ditemukan (46,2%). Gejala bersin-bersin ditemukan pada semua sampel dengan riwayat asma (100%). Riwayat atopi dalam keluarga ditemukan pada 12 orang (92,3%) sampel dengan riwayat asma. Kesimpulan: Kesimpulan penelitian ini yaitu riwayat asma ditemukan pada 1 dari 6 pasien rinitis alergi pada kelompok usia lebih dari 16 sampai 25 tahun. Pasien rinitis alergi dengan riwayat asma banyak ditemukan pada perempuan. Klasifikasi rinitis alergi terbanyak ditemukan berupa rinitis alergi persisten sedang-berat dengan gejala yang dominan yaitu bersin-bersin. Riwayat atopi dalam keluarga ditemukan pada sebagian besar pasien rinitis alergi disertai dengan riwayat asma.
Benefits of Conventional Chemotherapy in Progressive Disease Patients with Tyrosine-Kinase Inhibitors: A Case Report Ahmad Junaidi; Sabrina Ermayanti; Afriani Afriani
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 6 No. 14 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v6i14.657

Abstract

Background. Mutation of the epidermal growth factor receptor (EGFR) in non-small cell lung carcinoma is a favorable predictive factor for targeted EGFR tyrosine kinase inhibitor (TKI) therapy, but patients with EGFR-mutated lung cancer who are given EGFR-TKI will experience disease progression after average 10 to 14 months on average. This study aims to describe a case of progressive lung adenocarcinoma and its chemotherapy treatment. Case presentation: A 54 years old woman who came with stage IV left lung adenocarcinoma (exon 21 mutation) who had received EGFR TKI for 17 months progressed, so the treatment was shifted to systemic chemotherapy. Based on these diagnostic results, the patient was diagnosed with progressive disease T3N1M1c left lung adenocarcinoma (pleura, contralateral nodule, ribs, suprarenal) Stage IVb PS ECOG 0. The patient was then treated with conventional doublet-platinum-based chemotherapy with the Carboplatin-Paclitaxel combination. Conclusion: Systemic chemotherapy with doublet-platinum is an option in patients with progressive adenocarcinoma with EGFR-TKI who cannot obtain tissue for histopathological examination at rebiopsy or do not have access to advanced molecular biology (e.g., T790M) or follow-up therapy (third-generation TKI, osimertinib).
Effect of Radon and Lung Cancer Risk: A Narrative Literature Review Elsesmita; Sabrina Ermayanti; Dewi Wahyu Fitrina
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 6 No. 15 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v6i15.669

Abstract

Exposure to cigarette smoke has been known to be a major risk factor for lung cancer. Although smoking has long been considered the main cause of lung cancer, about 5 to 25% of lung cancer cases occur in non-smokers. Radon is said to be the second most important cause of lung cancer after smoking. Radon-222 is a chemical element in the form of a highly radioactive gas that comes from the decay of the parent radioactive element, uranium, which is found in the earth's crust. Inhaled radon gas can adhere to the mucosal lining of the airways and damage the airway epithelium. The process of ionizing radiation by alpha particles due to the decay of radioactive substances can cause mutations and chromosomal aberrations, severance of DNA double chains, and formation of reactive oxygen species. (ROS) that cause cell cycle changes, up-and down-regulation of cytokines, and increased production of proteins associated with cell cycle regulation and carcinogenesis. Research on radon and lung cancer has not been widely conducted in Indonesia. This literature review aims to describe radon and its effects on lung health.
Profile of Side Effects of Chemotherapy in Non-Small Cell Lung Cancer Patients (NSCLC) Undergoing Chemotherapy at Dr. M. Djamil General Hospital, Padang, Indonesia Isnaniyah Usman; Sabrina Ermayanti; Afriani Afriani
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 6 No. 16 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v6i16.704

Abstract

Background: Chemotherapy is one of the treatment options for lung cancer at any stage. Side effects due to chemotherapy are still a problem in the treatment of lung cancer patients. Chemotherapy drugs have different side effects according to their pharmacokinetics and pharmacodynamics. This study aimed to determine the side effects of both hematological and non-hematological chemotherapy in non-small cell lung cancer patients treated at the lung ward of Dr. M. Djamil General Hospital, Padang, Indonesia, from 2017 to 2019. Methods: This was a descriptive observational study, a total of 42 study subjects. The study subjects were non-small cell lung cancer patients undergoing first-line chemotherapy. Sociodemographic, clinical, and laboratory data analysis was carried out with the help of SPSS software in a univariate manner. Results: The study subjects were mostly male (85.36%), the age range of 40-60 years (66.67%), at risk of exposure from work (45.23%), smokers (59.52%), had a history of pulmonary TB (11.9%), history of COPD (2.38%), history of malignancy of other organs (2.38%) with the most cell type being adenocarcinoma (54.76%). The most common hematological side effects were first-degree anemia (21.43%) and first-degree leukopenia (21.43%). The most non-hematological side effects were first-degree alopecia (90.48%), followed by first-degree nausea and vomiting (78.57%). Conclusion: Chemotherapy side effects were found in all regimens given with mild degrees. The side effects obtained were in the form of hematological and non-hematological side effects.
High Levels of Leucocyte and Thrombocyte Increasing COVID-19 Mortality Rate in RSUP Dr. M. Djamil Padang Maulana Muharam; Sabrina Ermayanti; Afriani Afriani
Jurnal Respirologi Indonesia Vol 43, No 1 (2023)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v43i1.239

Abstract

Background: Different leukocytosis, leucopenia, thrombocytosis, thrombocytopenia, and clinical severity appear in COVID-19's cases. This study is aimed to identify the association between leucocyte, thrombocyte, and clinical severity in COVID-19's outcome.Methods: A retrospective cohort study involving 121 patients with COVID-19 whom admitted from January to March 2021. Kruskal Wallis test was applied for analysis.Results: The majority of participants were female (55.4%), aged between 18-49 years old (42.1%), and had comorbidities (81.8%). Most participants had a normal range of leucocyte (57.9%), thrombocyte (62.8%), and moderate clinical severity (67.8%). Subjects with full recovery were 79.3%, with sequelae such as weakness, and/or shortness of breath 3.3%, and deceased 17.4%. Leucocyte and thrombocyte had an association with COVID-19 outcome (P=0.045 and P=0.030 respectively). Clinical severity had no association with COVID-19 outcome (P=0.304). Conclusion: Leucocyte and thrombocyte have an association with COVID-19 outcome. Clinical severity has no association with COVID-19 outcome.
Immunotherapy in Lung Cancer: A Narrative Literature Review Hendris Utama Citra Wahyudin; Afriani Afriani; Fenty Anggrainy; Sabrina Ermayanti
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 1 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i1.755

Abstract

Lung cancer is the most common cause of death from cancer in both men and women worldwide. Cancers with low immunogenicity often do not present antigens, so immune responses can be avoided. Uncontrolled growth of tumor cells occurs due to various factors such as activation of immunosuppressive mechanisms, induction of various immunosuppressive cells, and expression of immune checkpoint molecules. The development of lung cancer management has progressed since the discovery of molecular-based target therapy and immunotherapy. The high expression of tumor mutational burden in lung cancer indicates high immunogenicity in lung cancer. Various immunological mechanisms involving programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have been developed for the treatment of lung cancer by utilizing immune system modulation. Nivolumab is the first approved immunotherapy for lung cancer, followed by pembrolizumab, atezolizumab, and durvalumab. The use of immunotherapy involving immune checkpoint inhibitors is an important breakthrough in the management of cancer, including lung cancer. This literature review aimed to describe immunotherapy in lung cancer that focuses on immune checkpoint inhibitors anti-PD-1 and anti-PD-L1.
Management of Resistance to Targeted Therapy in EGFR Mutational Lung Adenocarcinoma: A Case Report Armiza; Sabrina Ermayanti; Afriani
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 2 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i2.779

Abstract

Advances in diagnosis and treatment have enabled a targeted therapy approach to inhibit tumor progression and provide a favorable prognosis. One of the targeted therapies in non-small cell lung cancer (NSCLC) is tyrosine kinase inhibitor (TKI) in mutations epidermal growth factor receptor (EGFR). This study aimed to present a case with the management of resistance to targeted therapy in EGFR-mutated lung adenocarcinoma. Data shows median progression-free survival patients on TKI therapy at 10 to 14 months. Progressive caused by resistance to TKI and assessed using response evaluation criteria in solid tumors (RECIST) 1.1. and confirmed by repeat biopsy. Reported a male patient aged 66 years with adenocarcinoma of the right lung EGFR deletion exon 19 mutation and received afatinib therapy for 16 months. Patients experience oligo progressive in the 13th month of therapy and systemic progression 16th month.
Profil Pasien COVID-19 dengan Komorbid yang Dirawat di RSUP Dr. M. Djamil Padang Hamni Tanjung; Julizar Julizar; Sabrina Ermayanti; Deddy Herman; Liganda Endo Mahata; Syandrez Prima Putra
Jurnal Ilmu Kesehatan Indonesia Vol 4 No 1 (2023): Maret 2023
Publisher : Fakultas Kedokteran, Universitas Andalas

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25077/jikesi.v4i1.971

Abstract

Latar Belakang: Coronavirus Disease 2019 (COVID-19) yang disebabkan Severe Acute Respiratory Coronavirus-2 (SARS-CoV-2) telah menjadi perhatian dunia sejak awal ditemukan hingga saat ini. Keparahan kondisi pasien COVID-19 dengan komorbid dipengaruhi dengan berbagai faktor yang dapat meningkatkan morbiditas dan mortalitas pasien COVID-19. Objektif: Penelitian ini bertujuan untuk mengetahui profil pasien COVID-19 dengan komorbid yang dirawat di RSUP Dr. M. Djamil Padang. Metode: Jenis penelitian ini merupakan observasional deskriptif dengan pendekatan cross-sectional. Data penelitian diambil dari data rekam medis dengan teknik pengambilan total sampling pada pasien yang dirawat pada 1 Oktober sampai 31 Desember 2020. Hasil: Penelitian ini mendapatkan dari total 144 pasien, 34% pasien COVID-19 dengan komorbid merupakan kelompok usia 50-59 tahun, 50,7% berjenis kelamin laki-laki, 59,7% memiliki riwayat pendidikan tingkat menengah dan 53,5% berstatus IMT obesitas. Komorbid terbanyak yang ditemukan adalah 29,2% hipertensi dengan 73,6% pasien memiliki lebih dari satu komorbid, sebanyak 77,1% merupakan COVID-19 derajat sedang dengan 71,5% memiliki lama rawatan 14 hari atau kurang, serta 62,5% memiliki luaran COVID-19 sembuh. Kesimpulan: Penelitian ini menemukan sebagian besar pasien COVID-19 dengan komorbid yang dirawat merupakan kelompok usia tua, dengan komorbid terbanyak hipertensi, sebagian besar memiliki lebih dari satu komorbid, mengalami derajat sakit sedang dengan lama rawatan 14 hari atau kurang, dan luaran sembuh.
Indonesian Society of Respirology (ISR) Consensus Statement on Lung Cancer Screening and Early Detection in Indonesia Sita Andarini; Elisna Syahruddin; Nathaniel Aditya; Jamal Zaini; Ferry Dwi Kurniawan; Sabrina Ermayanti; Noni Novisari Soeroso; Sri Melati Munir; Andreas Infianto; Ana Rima; Ungky Agus Setyawan; Laksmi Wulandari; Haryati Haryati; Ida Ayu Jasminarti; Arif Santoso
Jurnal Respirologi Indonesia Vol 43, No 2 (2023)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v43i2.455

Abstract

Lung cancer is the leading cause of mortality for all cancer globally and in Indonesia. In Indonesia, lung cancer contributes to 12.6% of death of all cancer, making it the number one cause of cancer death, and 8.6% of all cancer incidence in 2018, behind breast, cervical, and colorectal cancer. The total cases per year are expected to almost double from 30,023 in 2018 to 54,983 cases in 2040. Smoking is among the risk factors for lung cancer, after occupational/environmental risk factors, history of lung fibrosis, and family history of cancer. There was a tendency of younger smokers in Indonesia and increased lung cancer incidence and prevalence in the younger population. The median age of lung cancer in Indonesia was younger than in any country, probably due to the younger age of smoking, early onset of carcinogens, asbestos use, and environmental. Lung cancer screening is a voluntary measure to detect lung cancer in the earliest stage, to find cancer at curable disease before symptoms appear in high-risk individuals. Lung cancer early detection is strategies to find cancer earlier after symptoms appear (cough, hemoptysis, dyspnea, chest pain). Low-dose computerized tomography of the thorax (LDCT) screening has been known to reduce lung cancer mortality compared to a chest x-ray (CXR). This Indonesian Society of Respirology consensus statement was aimed to give recommendations on lung cancer screening and early diagnosis in Indonesia.
LENT Score as a Prognosis Factor for Overall Survival and Progression-Free Survival in Malignant Pleural Effusion Patients at Tertiary Hospitals in West Sumatera, Indonesia Laisa Azka; Sabrina Ermayanti; Russilawati; Irvan Medison; Deddy Herman; Fenty Anggraininy
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 6 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i6.835

Abstract

Background: Malignant pleural effusion (MPE) has a variable survival rate and prognosis. The LENT score is one method for assessing survival rates in patients with MPE. This study aimed to investigate the LENT score as a prognostic factor for overall survival (OS) and progression-free survival (PFS) of patients with MPE at a tertiary hospital in West Sumatera. Methods: This study was an observational analytic study involving several tertiary hospitals in West Sumatera with a minimum observation period of 2 years. Data were collected from medical records. We used Kaplan Meier analysis to assess OS and PFS. Results: A total of 198 subjects met the inclusion criteria. Most MPE patients in this study were aged ≥60 years, male, smokers, pleural fluid lactate dehydrogenase value <1500, ECOG 1, serum NLR value <9, and high-risk cancer, namely lung cancer. The distribution of LENT scores for MPE patients was evenly distributed among the low, medium, and high-risk groups. Kaplan Meier analysis showed that the median OS based on LENT scores were 804 days, 275 days, and 161 days, respectively (log-rank test p = 0.000). The median PFS based on LENT scores were 715 days, 202 days, and 106 days, respectively (log-rank test p=0.000). The OS and PFS findings are longer than previous studies. Conclusion: Based on LENT scores, overall survival and progression-free survival MPE patients at tertiary hospitals in West Sumatera have a better prognosis compared to previous studies.
Co-Authors Afriani Sandra Ahmad Junaidi Amellya Sucieta Ana Rima Andreas Infianto Arif Santoso Armiza Dessy Mirzati Dewi Wahyu Fitrina Dewi Wahyu Fitrina Dian A. Juwita Dian Citra Dimas Bayu Firdaus Dolly Irfandy Elisna Syahruddin Elsa Purnama Sari Elsesmita Fenty Anggraini Fenty Anggraininy Fenty Anggrainy Ferry Dwi Kurniawan Hamni Tanjung Hansen Nasif Haryati Haryati Hendris Utama Citra Wahyudin Herman, Deddy Ida Ayu Jasminarti Irvan Madison Irvan Medison Irvan Medison Irvan Medison Isnaniyah Usman Julizar Julizar Laisa Azka Laksmi Wulandari Lilik Sulistyowati Mahata, Liganda Endo Masrul Basyar Masrul Basyar Maulana Muharam Mirtha Anggraeni Muhammad Farhan Ramadhan Muhammad Zakki Al-Fajri Nathaniel Aditya Noni Novisari Soeroso Oea Khairsyaf Russi lawati Russilawati, Russilawati Sari Nikmawati Setyawan, Ungky Agus Sita Andarini Sri Melati Munir Sukri Rahman Sur Yastri Syandrez Prima Putra Yandra Darusman Yessy Susanty Sabri Yori Yuliandra Zaini, Jamal